Skip to main content

Drug Interactions between Aliqopa and cholera vaccine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

cholera vaccine copanlisib

Applies to: cholera vaccine and Aliqopa (copanlisib)

If you are currently being treated or have recently been treated with copanlisib, you should let your doctor know before receiving cholera vaccine. Depending on the dose and length of time you have been on copanlisib, you may have a reduced response to the vaccine. In some situations, your doctor may want to delay vaccination to give your body time to recover from the effects of copanlisib therapy. If you have recently been vaccinated with cholera vaccine, your doctor may choose to postpone treatment with copanlisib for a couple of weeks or more. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

Moderate

cholera vaccine food

Applies to: cholera vaccine

Consumer information for this interaction is not currently available.

ADJUST DOSING INTERVAL: Coadministration of oral cholera vaccine with food or an oral beverage may impair its efficacy. The formulations of both the inactivated and live, attenuated oral cholera vaccines (Dukoral and Vaxchora, respectively) are acid-labile, and must be administered with a buffer. According to the manufacturer, eating and drinking may interfere with the protective effect of the buffer. However, clinical data are not available.

MANAGEMENT: It is recommended that patients avoid eating or drinking for 60 minutes before and after administration of either Dukoral or Vaxchora oral cholera vaccines.

References

  1. (2023) "Product Information. Vaxchora (cholera vaccine, live)." Patientric Ltd
  2. (2022) "Product Information. Dukoral (vibrio cholerae vaccine)." Valneva Sweden AB
  3. (2023) "Product Information. Dukoral (cholera vaccine)." Valneva UK Ltd
  4. (2024) "Product Information. Vaxchora (cholera vaccine, live)." Emergent Travel Health, Inc
View all 4 references
Moderate

copanlisib food

Applies to: Aliqopa (copanlisib)

Grapefruit juice can increase the blood levels of copanlisib. This may increase side effects such as nausea, vomiting, diarrhea, mouth sores, high blood sugar, high blood pressure, lung or breathing problems, severe skin reactions, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You should avoid the consumption of grapefruit and grapefruit juice during treatment with copanlisib. Talk to your doctor or pharmacist if you have questions on this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.